# VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer

> **NCT05489731** · PHASE1 · UNKNOWN · sponsor: **Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.** · enrollment: 72 (estimated)

## Conditions studied

- Advanced Non-small Cell Lung Cancer

## Interventions

- **DRUG:** VIC-1911
- **DRUG:** Osimertinib Mesylate Tablets

## Key facts

- **NCT ID:** NCT05489731
- **Lead sponsor:** Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-21
- **Primary completion:** 2024-02-24
- **Final completion:** 2024-04-24
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2023-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05489731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05489731, "VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05489731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*